Identification of immunotherapy early treatment failure in non-small cell lung cancer (NSCLC) using a novel cell-free DNA (cfDNA) tissue-agnostic genome-wide methylome enrichment assay.
Tuan Hoang(University Health Network), Adrian G. Sacher(Princess Margaret Cancer Centre), Sally C. M. Lau(University Health Network), Yahan Yang(University Health Network), Brian Allen(Myriad Genetics), Lawson Eng(Princess Margaret Cancer Centre), Scott V. Bratman(University Health Network), Ben Brown, Anne‐Renee Hartman, Frances A. Shepherd(University Health Network), Justin Burgener, Collin Melton(Menlo School), Jing Zhang(Technology Holding (United States)), Geoffrey Liu(Princess Margaret Cancer Centre), Daniel D. De Carvalho(University Health Network), Penelope Ann Bradbury(University Health Network), Elena Elimova(University of Toronto), Miguel García-Pardo(Hospital Universitario Ramón y Cajal), Abigail Williams(University of Oxford), Natasha B. Leighl(Princess Margaret Cancer Centre)
Cited by 1
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
|The Lancet|2014|1.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k